Last reviewed · How we verify
NCT05417737: EPOOzo
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025
trial testing Ozone therapy in Radiation Toxicity in 105 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Bernardino Clavo, MD, PhD |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 105 |
| Start date | 15 June 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Ozone therapy — full drug profile →
Conditions studied
- Radiation Toxicity — all drugs for Radiation Toxicity →
- Chemotherapeutic Toxicity — all drugs for Chemotherapeutic Toxicity →
- Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
- Delayed Wound Healing — all drugs for Delayed Wound Healing →
Sponsor
Bernardino Clavo, MD, PhD — full company profile →
Who can join
18 and older, any sex, with Radiation Toxicity or Chemotherapeutic Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effects of Ozone Treatment on Health-Related Quality of Life and Toxicity Induced by Radiotherapy and Chemotherapy in Symptomatic Cancer Survivors.
Clavo B, Cánovas-Molina A, Ramallo-Fariña Y, Federico M, et al · · 2023 · cited 10× · PMID 36674232 · DOI 10.3390/ijerph20021479 -
Ozone in Chemotherapy-Induced Peripheral Neuropathy-Current State of Art, Possibilities, and Perspectives.
Szklener K, Rudzińska A, Juchaniuk P, Kabała Z, et al · · 2023 · cited 8× · PMID 36982352 · DOI 10.3390/ijms24065279 -
Effects of ozone therapy on anxiety and depression in patients with refractory symptoms of severe diseases: a pilot study.
Clavo B, Cánovas-Molina A, Díaz-Garrido JA, Cañas S, et al · · 2023 · cited 6× · PMID 37599784 · DOI 10.3389/fpsyg.2023.1176204 -
Effects of ozone treatment on chemotherapy-induced peripheral neuropathy: a promising research area.
Clavo B, Cánovas-Molina A, García-Lourve C, Cazorla-Rivero S, et al · · 2025 · PMID 40070187 · DOI 10.4103/mgr.medgasres-d-24-00074
Verify or expand the search:
- PubMed search for NCT05417737
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ozone therapy
Trials testing the same drug.
- NCT07069153 — Laser vs Ozone Therapy for Oral Mucositis in Cancer Patients · NA · completed
- NCT07035522 — Ozone Therapy for Women With Endometriosis · NA · not yet recruiting
- NCT06954870 — Effect of Systemic and Local Ozone Therapy in Lipedema · NA · completed
- NCT06799351 — Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). · Phase 2, PHASE3 · recruiting
- NCT06706544 — Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy · Phase 2, PHASE3 · recruiting
Other recruiting trials for Radiation Toxicity
Currently open trials in the same condition.
- NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting
- NCT06311968 — The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor · Phase 2 · recruiting
- NCT05530655 — A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy · EARLY_PHASE1 · recruiting
- NCT06215495 — A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial · NA · recruiting
- NCT06033183 — Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology · NA · recruiting
Other Bernardino Clavo, MD, PhD trials
Trials by the same sponsor.
- NCT07259681 — Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox) · not yet recruiting
- NCT07325851 — Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029. · not yet recruiting
- NCT06816095 — Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Seconda · recruiting
- NCT06799351 — Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). · Phase 2, PHASE3 · recruiting
- NCT06706544 — Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05417737 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bernardino Clavo, MD, PhD
- Last refreshed: 2 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417737.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing